title: Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Eur Urol 2003;44:512-8.
authors.forename: Andrea
authors.initials: A
authors.lastname: Tubaro
authors.forename: Cosimo
authors.initials: C
authors.lastname: De Nunzio
mesh_terms: D000813:Anilides / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D006801:Humans; D008297:Male; D009570:Nitriles; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors; D014105:Tosyl Compounds
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen